v3.26.1
Acquisition of Soleno Therapeutics, Inc. - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 3 Months Ended 6 Months Ended
May 18, 2026
Jun. 30, 2026
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Developed product rights            
Business Combination [Line Items]            
Useful life of developed product rights (in years)   16 years 16 years   16 years  
Soleno Therapeutics, Inc.            
Business Combination [Line Items]            
Business combination (in dollars per share) $ 53.00          
Purchase price for the soleno acquisition related to soleno shares $ 67.4          
Share-based compensation expense     $ 60.1   $ 60.1  
Acquisition-related costs   $ 104.7 $ 33.1 $ 0.0 $ 33.1 $ 0.0
Total revenues to soleno   54.4        
Net income (loss) attributable to soleno   $ (52.2)        
Soleno Therapeutics, Inc. | Minimum            
Business Combination [Line Items]            
Inventory step-up amortization period (in years) 4 years          
Soleno Therapeutics, Inc. | Maximum            
Business Combination [Line Items]            
Inventory step-up amortization period (in years) 6 years          
Soleno Therapeutics, Inc. | VYKAT XR | Developed product rights            
Business Combination [Line Items]            
Discount rate (as percent) 24.00%          
Soleno Therapeutics, Inc. | VYKAT XR | Maximum | Developed product rights            
Business Combination [Line Items]            
Useful life of developed product rights (in years) 16 years          
Soleno Therapeutics, Inc. | VYKAT XR | Work In Process            
Business Combination [Line Items]            
Inventory fair value, step-up $ 41.5          
Soleno Therapeutics, Inc. | VYKAT XR | Finished Goods            
Business Combination [Line Items]            
Inventory fair value, step-up $ 126.7